
|Articles|November 13, 2009
Diabetes & Obesity Podcasts: Obesity Drugs and Co-Morbidities
Advertisement
Diabetes & Obesity Series
Obesity Drugs and Co-Morbidities
Subscribe to RSS feed of this series
Dr. Richard Gregg
Chief Scientific Officer
Vitae Pharmaceuticals
Dr. Gregg offers insight into the development of obesity drugs, and how co-morbidities factor into development, as well as how it impacts sites and CROs in Phase I through III trials.
Others in the Series
Diabetes Resources
- Articles, Multimedia
Diabetes Drugs in Development, 2009
Associations and Societies
Clinical Trials
Obesity Resources
Articles, Multimedia
Associations and Societies
Clinical Trials
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Nipocalimab Delivers Positive Phase IIb Results in JASMINE SLE Trial
2
Fresh Starts, Real Readiness: Turning Site Initiation into a Trial Success Multiplier
3
ACT Brief: Rethinking Representation in Cancer Trials, Positive Phase IIb SLE Data, and a Major Obesity Drug Partnership
4
ACT Brief: Reframing Site Initiation Readiness, Operational Execution as Competitive Advantage, and a Historic Motion Sickness Approval
5




